Xanthine Oxidase (XO) 學生 : 李威聰 指導老師 : 李惠春. Introduction  Function  Structure  Property  Gout.

Slides:



Advertisements
Similar presentations
Copyright © 2015 Cengage Learning® Chapter 15 Urinary System Drugs.
Advertisements

1 Oxypurinol for Gout Arthritis Drugs Advisory Committee June 2, 2004 Cardiome Pharma Corp Vancouver, BC Canada.
1. Describe the pathogenesis of hyperuricemia and gout Goup C1 Group C1.
TXF Caveat on urate levels Serum uric acid level may be normal at the time of an acute attack. Normal level does not rule out gout. May be better.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Purine Degradation & Gout (Musculoskeletal Block)
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Nucleic acids metabolism
Arthritis New Zealand Gout Georgina Greville RN Arthritis Educator.
Gout.
 Gout is characterized by elevated uric acid concentrations in blood and urine due to variety of metabolic abnormalities that include overproduction.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Purine degradation & Gout (Musculoskeletal Block).
 From normal turnover of cellular nucleic acids  Obtained from the diet  Reutilization of adenine, hypoxanthine, and guanine  Two enzymes: 1.
Uric acid xiaoli.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
Purine Degradation & Gout (Musculoskeletal Block)
Chapter 13 Agents Used to Treat Hyperuricemia and Gout.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Uric Acid Metabolism & Gout
Anti-Inflammatory & Immunosuppressive Drugs 2
GOUT TREATMENT. Gout prevalence doubled over the last 20 yrs. Factors? - longevity - diuretic use - low dose ASA - obesity - end stage renal disease -
FCH 532 Lecture 31 Chapter 28: Nucleotide metabolism
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Dr. Karen Vieira & Shawn Stevenson
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Agents Used to Treat Hyperuricemia and Gout
Gout. The most common cause of inflammatory arthritis in US adults (3.9% of Americans; approx. 8.3 million people; ) Prevalence is greater in.
CYP Biotransformations
HS140: Pharmacology Week 6: Analgesics/Antipyretics Musculoskeletal System and Disorders.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
StagesClinical Features (1)Asymptomatic hyperuricemiahigh uric acid level is present but without symptoms (2) Acute Gouty Arthritishigh uric acid level.
Anna Pardue NS Methodist University.  As we known “Rich man’s disease.”  Inflammatory arthritis, a metabolic disorder that causes the deposition of.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Colchicine: Colchicine: Effective & specific gout Rx, but less favored than NSAIDs because of slow onset of action & high incidence of side effects. Effective.
Creatinine Creatinine is the waste product formed in muscle from a high energy storage compound ,creatine phosphate (phosphocreatine). ATP is the immediate.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
ANTI-GOUT DRUGS. GOUT A familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate in joints.
Uric acid nephropathy 신장내과 R4 최선영. Endogenous production of uric acid Purine catabolism hypoxanthine xanthine Uric acid allantoin XO UO allopurinol -
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
GOUT GOUT.
Purine degradation and Gout
Purine Degradation & Gout (Musculoskeletal Block)
Gout.
Introduction to pathology
Drug Therapy of Gout 1.
The action of xanthine oxidase in uric acid synthesis and metabolism of allopurinol. (Modified and reproduced, with permission, from Katzung BG, editor:
PURINE AND PYRIMIDINE DEGRADATION
  URIC ACID Muthana A. Al-Shemeri.
Antiuricaemic drugs Dr A.W Olusanya.
Gout By: Patience Alley, Albert Watson, and Hunter Kimball.
Desorders of nucleotides metabolism
Pu & Py salvage Title slide..
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
 The word ‘gout’ is derived from the Latin word ‘gutta’.  Earlier it was believed that an acute attack of the disease was the result of poison dropping.
Purine Degradation & Gout (Musculoskeletal Block)
Regulation of uric acid metabolism and excretion
Purine Degradation & Gout (Musculoskeletal Block)
Volume 10, Issue 1, Pages (January 2002)
Presentation transcript:

Xanthine Oxidase (XO) 學生 : 李威聰 指導老師 : 李惠春

Introduction  Function  Structure  Property  Gout

Function  In purine degradation, it oxidizes hypoxanthine successively to xanthine and then to uric acid

Stucture  Homodimer  Each monomer has three domains  N-terminal domain (residues 1~165):  N-terminal domain (residues 1~165): two Fe/S cofactors two Fe/S cofactors  FAD-binding domain (residues  FAD-binding domain (residues 226~553) 226~553)  The third domain (residues  The third domain (residues 590~1332): one molybdenum 590~1332): one molybdenum

 Fe/S  convert XDH (xanthine dehydrogenase) to XO dehydrogenase) to XO FAD  reduction of O 2 FAD  reduction of O 2 Molybdenum  oxidative hydroxylation Molybdenum  oxidative hydroxylation of purine of purine

Property  Ubiquitous among species and within the various tissues  Normally it exists in the liver and jejunum  determination of serum xanthine  determination of serum xanthine oxidase level serves as a sensitive oxidase level serves as a sensitive indicator of acute liver damage indicator of acute liver damage

 In individuals, 90% is XDH form, and 10% is XO form 10% is XO form  XDH  XO (oxidation of sulfhydryl or  XDH  XO (oxidation of sulfhydryl or proteolysis) proteolysis)  Difference between XO & XDH: XO  XH+H 2 O+O 2  X=O+H 2 O 2 XO  XH+H 2 O+O 2  X=O+H 2 O 2 XDH  XH+H 2 O+NAD +  X=O+NADH XDH  XH+H 2 O+NAD +  X=O+NADH

 Other names: xanthine oxidoreductase, hypoxanthine oxidase, hypoxanthine- xanthine oxidase

Gout  A form of arthritis caused by excess uric acid (hyperuricemia)  Complication can result death  Cause: heredity, diet, fatness, sex, excessive exercise, drug, alcohol, and some diseases

 Drug can decrease patients’ pains and prevent it  an attack of acute gout: colchicine  an attack of acute gout: colchicine  lower conc. of uric acid: allopurinol  lower conc. of uric acid: allopurinol